Nonmyeloablative peripheral blood stem cell transplantation (PBSCT) is a novel therapeutic strategy for patients with malignant and non-malignant hematologic diseases. Infectious complications of this procedure have not been previously well described. Data on 12 patients transplanted at a tertiary care center were collected prospectively and verified retrospectively. Neutropenia developed in a third of patients, lasting for a median of 5 days. All patients developed some degree of graft-versus-host disease, as intended. Most patients achieved full chimerism by week 5. Bacterial infections occurred in two patients (17%). Cytomegalovirus (CMV) viremia occurred in five patients (42%) at a median of 80 days; none had received CMV prophylaxis. Viremia was associated with fever and fatigue in three patients, possible gastrointestinal involvement in one patient and was asymptomatic in one patient. All viremic patients responded to intravenous ganciclovir therapy. No fungal infections were documented. No patients died as a result of infection. The incidence of CMV viremia in our patients was high, but the incidence of invasive disease due to CMV was low. The best strategy to prevent CMV in patients undergoing nonmyeloablative PBSCT remains to be determined, but strategies employed in traditional allogeneic bone marrow transplantation should be considered in these patients. graft-versus-leukemia (GVL) effect is important in preventing relapse after alloBMT.
graft-versus-leukemia (GVL) effect is important in preventing relapse after alloBMT. 1 Studies have shown that patients who develop graft-versus-host disease (GVHD) after allo BMT are at lower risk of relapse. 2 Additionally, patients relapsing after alloBMT for leukemia may have a chance of cure with donor lymphocyte infusion, on the basis of inducing a GVL effect. 3 During the last few years, several investigators have embarked on studies of nonmyeloablative alloBMT or peripheral blood stem cell transplantation (PBSCT) for malignant and non-malignant hematologic diseases, 4, 5 as well as for non-hematologic malignancies, 6 with encouraging results. In this approach, patients receive a minimal conditioning regimen that is sufficient to prevent acute rejection of donor hematopoietic cells. The entire strategy relies on the GVL effect or the graft-versus-tumor effect as the primary therapeutic modality. A nonmyeloablative preparative regimen may actually reduce acute GVHD by diminishing release of inflammatory cytokines, reduce regimen-related toxicity, and reduce early neutropenia associated with traditional alloBMT. 7 The only published study describing the infectious complications in patients undergoing nonmyeloablative BMT reported a high rate of cytomegalovirus (CMV) and gramnegative bacterial infections. 8 We present our data on the infectious complications occurring within the first year after transplantation in 12 patients who received nonomyeloablative PBSCT at our institution.
Patients and methods
From January 2000 to December 2000 12 patients were enrolled in this protocol. Only patients who were well enough (ECOG performance status 0 or 1) to receive the entire preparative regimen and the allogeneic PBSCT as outpatients were enrolled. All 12 patients had adequate renal, hepatic, cardiac and pulmonary functions and an estimated life expectancy of у100 days. These patients were considered ineligible for 'conventional' myeloablative alloBMT because of advanced age, or because high-dose chemotherapy was not likely to be curative. Donors were HLA-matched siblings, who received granulocyte colonystimulating factor (G-CSF) 10 g/kg subcutaneously daily Bone Marrow Transplantation for stem cell mobilization, followed by leukopheresis performed on a COBE Spectra machine (COBE, Denver, CO, USA) on the 5th day. The minimum number of CD34 ϩ cells collected was 2.0 ϫ 10 6 cells/kg. All patients had tunneled central venous catheters inserted before transplantation. The preparative regimen consisted of fludarabine 30 mg/m 2 intravenously (i.v.) on days Ϫ4, Ϫ3 and Ϫ2 (total three doses), followed by 200 cGY of total body irradiation (TBI) on day 0; lung blocks were not utilized. On day 0 and day ϩ1, donor stem cells were infused. Leukocyte-depleted blood products were used for transfusion support. Patients whose absolute neutrophil count (ANC) decreased to р1500 ϫ 10 6 cells/l were given G-CSF 10 g/kg/day i.v. until the ANC exceeded 1500 ϫ 10 6 cells/l for 2 consecutive days. Oral cyclosporine A (CsA) 200 mg/day and mycophenolate mofetil (MMF) 1500 mg/day were used for primary GVHD prophylaxis and for the prevention of graft rejection until day ϩ56. Treatment of GVHD consisted of oral prednisone starting at a dose of 0.3 mg/kg/day and CsA, with or without MMF. Grading of GVHD 9 and mucositis 10 was assessed according to standard criteria in the literature.
Antimicrobial prophylaxis consisted of oral amoxicillin 250 mg twice daily, acyclovir 400 mg twice daily and itraconazole cyclodextrin solution 200 mg/day commencing on day ϩ5. If the ANC decreased р1000 ϫ 10 6 cells/l, amoxicillin was discontinued and patients were started on i.v. vancomycin 1 g twice daily, oral ciprofloxacin 500 mg twice daily and clarithromycin 250 mg twice daily. In addition, when patients were started on prednisone for treatment of GVHD, oral trimethoprim 160 mg/ sulfamethoxazole 800 mg given every other day was commenced. If the prednisone dose exceeded у40 mg/day, prophylactic i.v. amphotericin B was instituted at a dose of 0.5 mg/kg three times weekly. The first 10 patients on this protocol did not receive any form of CMV prophylaxis. The protocol was then amended as follows: if patients or donors were serologically CMV positive, i.v. ganciclovir was administered at a dose of 5 mg/kg/day commencing when the ANC was у2000 ϫ 10 6 cells/l for 2 days off G-CSF and when patients were no longer platelet transfusiondependent. Ganciclovir prophylaxis was continued until day ϩ100. Similarly, only after the 10th patient was enrolled did we perform weekly CMV DNA detection in blood by a hybrid capture assay (Digene, MD, USA), reported as copies/ml. Patients with any positive result on this assay were treated with ganciclovir 5 mg/kg twice daily for 3 weeks, or longer if the assay remained positive. CMV viremia was considered symptomatic when accompanied by fever, chills, or malaise for 3 or more days without other explanation. CMV disease was defined as histologic evidence of target organ involvement.
Quantitative immunoglobulins were checked before and biweekly after transplantation and supplemental intravenous immunoglobulin (IVIG) was administered if the total IgG level was Ͻ7 g/l. Neutropenia was defined as an ANC р500 ϫ 10 6 cells/l and the duration of neutropenia was defined as the number of days with an ANC р500 ϫ 10 6 cells/l. Lymphopenia was defined as an absolute lymphocyte count (ALC) р1000 ϫ 10 6 cells/l. Severe thrombocytopenia was defined as a platelet count р20 ϫ 10 9 cells/l and the duration of severe thrombocytopenia was defined as the number of days with a platelet count р20 ϫ 10 9 cells/l. Samples of peripheral blood were examined for chimerism at regular intervals after transplantation using polymerase chain reaction of informative variable number tandem repeats (VNTR) loci in both buffy coat leukocytes and T cell (CD3 ϩ )-enriched fractions. Data on infectious complications, GVHD, engraftment and chimerism were collected prospectively as they occurred. All clinical, radiological and microbiological records were retrospectively reviewed and verified.
Results

Demographic data (Table 1)
Median patient age was 57 years (range 39 to 62 years). Eight patients were female and four were male. Underlying diseases requiring transplantation included MDS (n = 3), CML (n = 2), CLL (n = 2) (one of which also had Wälden-strom's macroglobulinemia), AML (n = 2), MM (n = 2) and NHL (n = 1). Five patients (42%) had received previous autologous PBSCT, but had subsequently relapsed. The median time from diagnosis to allo PBSCT was 15.5 months (range 3 to 152 months). Seven donors were female and five were male. Donor/recipient (D/R) gender mismatch was present in three patients. CMV serologic status was: Dϩ/Rϩ (n = 8), Dϩ/RϪ (n = 2) and DϪ/RϪ (n = 2). The median dose of CD34 ϩ cells infused was 6.9 ϫ 10 6 cells/kg (range 2.04 to 7.03 ϫ 10 6 cells/kg). Patients were followed for a median of 155 days (range 30 to 280 days) from the date of transplantation.
Toxicity
All patients tolerated the preparative regimen and alloPBSCT well, with the exception of one patient (8%), who developed severe nausea and was unable to maintain oral intake. Three patients (25%) developed oral mucositis; one patient had grade I and two patients had grade II mucositis. Four patients (33%) became neutropenic for a median duration of 5 days (range 2 to 7 days), none of which had an ANC Ͻ150 ϫ 10 6 cells/l (lowest ANC was 178 ϫ 10 6 cells/l, 248 ϫ 10 6 cells/l, 269 ϫ 10 6 cells/l and 300 ϫ 10 6 cells/l for these four patients). Three patients (25%) developed severe thrombocytopenia for a median duration of 1 day (range 1 to 5 days), but all three were thrombocytopenic before transplantation. All patients developed lymphopenia and the median lowest ALC was 0.06 ϫ 10 6 cells/l (range 0 to 0.23 ϫ 10 6 cells/l). All patients developed hypogammaglobulinemia at a median of 41 days post transplant and received IVIG replacement therapy. None developed veno-occlusive disease. Seven patients (58%) required subsequent hospitalization at a median of 9 days after transplantation (range 4 to 96 days), four of whom were hospitalized more than once. Reasons for hospitalization included management of GVHD, neutropenic fever, severe nausea, pneumonia, bacteremia, meningoencephalitis and chest pain. AML = acute myelogenous leukemia; CR2 = second complete remission; CLL = chronic lymphocytic leukemia; CVP = cyclophosphamide, vincristine, prednisone; NHL = non-Hodgkin's lymphoma; CHOP = cyclophosphamide, adriamycin, vincristine, prednisone; PBSCT = peripheral blood stem cell transplantation; XRT = radiation therapy; VAD = vincristine, adriamycin, decadrone; VBMCP = vincristine, BCNU (carmustine), melphalan, cyclophosphamide, prednisone; PR3 = third partial remission; CML = chronic myelogenous leukemia; MDS = myelodysplastic syndrome; WMG = Wälden-strom's macroglobulinemia.
GVHD and chimerism
All patients developed some degree of GVHD. GVHD involved the skin in all patients, the gastrointestinal tract in six (50%) and the liver in two (17%). Six patients (50%) had more than one organ affected by GVHD. Seven patients (58%) had grade I GVHD, two (17%) had grade II GVHD, two (17%) had grade III GVHD and one patient (8%) had grade IV GVHD. All three patients with D/R gender mismatch had more than one organ affected by GVHD and all had grade II GVHD or more. In contrast, six of nine patients with D/R gender match had only one organ affected by GVHD and seven had grade I GVHD. By week 5 after transplantation, nine patients (75%) had 100% donor cells, two (17%) had 95% donor cells and one (8%) had 90% donor cells.
Infectious complications
Bacterial infections: Two patients (17%) had central venous catheter-related bacteremias, one on day ϩ21 and the other on day ϩ30. Neither patient was neutropenic following transplantation. Causative organisms were Acinetobacter calcoaceticus-baumannii complex, Pseudomonas species (not aeruginosa) (both in the same blood culture) and coagulase-negative Staphylococcus (isolated in five consecutive blood cultures). The patient with gram-negative bacteremia did not have GVHD of the gastrointestinal tract at the time of bacteremia. Bacteremia resolved in both patients following a course of i.v. antibiotic therapy and the indwelling central venous catheter was removed in one patient.
CMV infection: Five patients (42%) developed CMV viremia. All five were CMV Dϩ/Rϩ. None of these patients had received CMV prophylaxis with ganciclovir. One patient had asymptomatic viremia, three patients had fever and/or fatigue associated with viremia and one had possible gastrointestinal involvement associated with viremia, with a colon biopsy suggestive of infection, but not conclusive for CMV disease. Viremia developed a Bone Marrow Transplantation median of 80 days following transplantation (range 13 to 130 days) and a median of 17 days after the development of GVHD (range 0 to 85 days). Median ALC at the onset of CMV viremia was 0.40 ϫ 10 6 cells/l (range 0.26 to 0.99 ϫ 10 6 cells/l). Median viral load at the onset of viremia was 3204 copies/ml (range 1686 to 16 367 copies/ml) and the median peak viral load was 3270 copies/ml (range 1686 to 16 367 copies/ml). The median duration of viremia was 1 day (range 1 to 51 days), with three patients being viremic only on a single occasion. In three patients, treatment with ganciclovir for 3 weeks resulted in resolution of viremia. The other two patients were treated for longer periods, but eventually cleared the viremia.
Other clinically diagnosed infections:
One patient had oral thrush on day ϩ55 and improved with oral fluconazole. Another had an infection along the tunnel of an indwelling central venous catheter on day ϩ27 while neutropenic, associated with deep venous thrombosis in the related vein. Blood cultures and catheter tip cultures were both negative. She improved with removal of the catheter, anticoagulation and empiric i.v. vancomycin for 2 weeks.
One patient, who was never neutropenic, was diagnosed with pneumonia on day ϩ21. Blood cultures for bacteria, serum cryptococcal antigen, CMV DNA, histoplasma urinary antigen by enzyme immunoassay, serologies for aspergillus, histoplasma, coccidioides and blastomyces by complement fixation and immunodiffusion methods, stains and cultures from broncheoalveolar lavage for bacteria, fungi, mycobacteria, nocardia, mycoplasma, legionella, CMV, herpes simplex virus, adenovirus and Pneumocystis carinii were all negative and a transbronchial biopsy showed acute lung injury consistent with infection or chemotherapy effect. She improved with broad-spectrum antibacterial agents.
One patient developed meningoencephalitis on day ϩ102. Brain magnetic resonance imaging was normal. Cerebrospinal fluid cytology, cryptococcal antigen, cultures for bacteria, fungi and mycobacteria, as well as polymerase chain reactions for CMV, varicella zoster virus and herpes simplex virus were all negative. She slowly improved with broad-spectrum antibacterials, ganciclovir and amphotericin B.
Outcome
None of the patients died as a result of infection. All patients survived for more than 30 days from transplantation. One patient (8%) died on day ϩ73 with multi-system organ failure related to GVHD. Seven patients (58%) are in complete remission, four (33%) are in partial remission. One patient (8%) relapsed with MDS 120 days after transplantation.
Discussion
Several differences exist between our patients who received nonmyeloablative alloPBSCT and those who receive 'conventional' myeloablative alloBMT, which may have affected the incidence of infectious complications. In general, our patients were older, but had an excellent performance status. Almost half of our patients had previously received autologous PBSCT, but subsequently relapsed thereafter. None were hospitalized to receive the preparative regimen or for infusion of the donor stem cells and thus none were initially managed in private rooms.
Clearly, what stands out in our patients is the relatively high incidence of CMV viremia (42%). Despite this high rate of CMV viremia, none of the patients developed CMV pneumonia. In the era before the introduction of specific CMV prophylaxis, about one third of patients receiving alloBMT developed CMV disease. 11 With current antiviral prophylaxis measures, the peak incidence of CMV disease has shifted from around day ϩ50 to day ϩ100 or later. 12 In a recent study from Germany, 13 the incidence of CMV antigenemia and CMV-related interstitial pneumonia was lower in 'conventional' myeloablative alloPBSCT recipients compared to BMT recipients; suggesting improved immune reconstitution following PBSCT compared to BMT. None of our patients who developed CMV viremia had received CMV prophylaxis. Several risk factors for the development and severity of CMV disease after alloBMT have been identified, including GVHD, DϪ/Rϩ serostatus, 14 conditioning regimens that include TBI, 15 lymphopenia (particularly of CD4 ϩ T cells 16 ) and transplantation from unrelated donors. 17 All our patients who were viremic with CMV, were CMV donor and recipient seropositive, lymphopenic and had GVHD before the onset of viremia. It is difficult to compare the peak CMV viral load and duration of viremia that occurred in our patients to other patients in the literature following alloBMT, because of the wide variability in the diagnostic and prophylactic measures for CMV employed by various transplant programs. 18 The French study by Mohty et al 8 found a significantly higher rate (65%) of early CMV infection (median 31 days post transplantation) in patients undergoing nonmyeloablative alloBMT. Interestingly, CMV infection preceded the development of GVHD in all their patients. These investigators used the CMV antigenemia assay (CINAkit; Argene Biosoft, Varilhes, France) to detect CMV infection and to trigger the implementation of pre-emptive therapy with ganciclovir. None of their patients apparently developed CMV-related disease. We suspect that the difference in the incidence of CMV viremia between our study and the latter study may be attributed to several factors: (1) the different preparative regimens used (their regimen consisted of fludarabine, busulfan and anti-lymphocyte globulin, while ours was fludarabine and low-dose TBI); (2) the lower median dose of CD34 ϩ cells infused by Mohty et al (theirs was 2.3 ϫ 10 6 cells/kg, while ours was 6.92 ϫ 10 6 cells/kg); (3) the different preventive strategies used for CMV (they used a pre-emptive strategy, while we only used a universal prophylaxis strategy after the 10th patient was enrolled); or (4) simply (and most likely) due to chance alone, because of small numbers in both studies (theirs included 21 patients and ours 12 patients).
Of additional interest, the study by Mohty et al 8 found a high rate (33%) of late (median 124 days post transplantation) bacterial infections, predominantly gramnegative bacteremias. All their patients became neutropenic, but all had engrafted long before the onset of bacteremia. In contrast, only two (17%) of our patients were bacteremic. In both patients this occurred early after transplantation, but neither was neutropenic at the time of bacteremia. Again, the difference in our experience compared to that of Mohty et al may be attributed to: (1) all their patients were treated as inpatients, exposing them to various nosocomial organisms, while ours were treated as outpatients, at least initially; (2) all their patients became neutropenic, for a median duration of 13 days, while only four (33%) of our patients were neutropenic, for a median duration of 5 days; (3) our aggressive antimicrobial prophylaxis regimen, including IVIG; or, again; (4) simply (and most likely) due to chance alone. Data on the incidence and severity of mucositis are not documented in Mohty's study, but would probably have been unrelated to the occurrence of late bacteremias. Similarly, the relationship of the development of GVHD of the gastrointestinal tract to the occurrence of bacteremia was not documented in their study.
No documented fungal infections were encountered in the study by Mohty et al, or in our study. This may be attributed to the vigorous antifungal prophylaxis measures used in both studies and to the low incidence and short duration of neutropenia in our study.
Perhaps the most important difference between these studies is the fact that all patients in the study by Mohty et al were treated as inpatients in private rooms, while ours were not. All our patients were well enough to receive the entire preparative regimen and the PBSCT as outpatients, which was certainly more convenient. Although a formal cost analysis has not been performed, one would expect a significant cost saving compared to treating inpatients in private rooms.
In summary, patients receiving nonmyeloablative alloPBSCT had a significant incidence of CMV viremia, but a low incidence of invasive CMV disease, even in the group that did not receive ganciclovir prophylaxis. This high rate occurred despite the fact that none of our patients were at the highest risk of developing CMV-related compli-cations (DϪ/Rϩ serostatus). The rate of asymptomatic CMV viremia may have been underestimated, since weekly CMV DNA detection in blood was performed only after the 10th patient was enrolled in this protocol. There is currently insufficient evidence to recommend a prophylaxis strategy vs a pre-emptive monitoring strategy in these patients, 18, 19 but this high rate of CMV viremia suggests that one of these two strategies should be employed. The lower incidence of invasive CMV disease compared with past literature in unprophylaxed alloBMT recipients suggests that the biology and timetable of occurrence of infection in this nonmyeloablative group may be somewhat different from recipients of 'conventional' alloBMT. Infections other than CMV did occur, but were readily treatable, with the exception of the patient with meningoencephalitis, who eventually recovered after a protracted course. The absence of invasive fungal infections in our patients is probably related to the low incidence and severity of neutropenia. The absence of deaths from sepsis or other severe infections is encouraging. The spectrum of infectious complications after nonmyeloablative BMT and PBSCT, as well as the optimal preventive antimicrobial regimen in this setting, remain to be further defined.
